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showed , 70% similarity (Figure 1) and were considered unre-
lated. Multilocus sequence typing (MLST) analysis showed that iso-
lates of the outbreak strain had an identical allelic profile, ST17
belonging to the clonal complex 17 (CC-17). Four E. faecium iso-
lates were used as controls in the MLST analysis, two vancomycin-
susceptible isolates from HGS had the ddl2 allele, instead of
the ddl1 of the vanB2 isolates, and belonged to ST16; and
two other vanB producers from other hospitals were ST18 and
ST132.
Infections caused by VanB vancomycin-resistant E. faecium
belonging to CC-17 are still relatively uncommon in Europe.
In two hospitals in Zaragoza (Spain), a clonal relationship
was demonstrated between seven vanB2-containing E. faecium
isolates.4 The first VanB E. faecium isolated in a Spanish
hospital was described in 2004.5 In Sweden, a nosocomial out-
break of VanB2 E. faecium with the purK allele 1 has been
reported.6
An enhanced infection control programme was introduced in
the HGS during 2006. Patients infected by VanB enterococci
were isolated in single rooms whenever possible, and these
rooms were mechanically cleaned each day. The outbreak of
VanB E. faecium finished in August 2006, with no further cases
detected.
In conclusion, to the best of our knowledge, we describe the
first outbreak in Spain of a vanB2 E. faecium strain belonging
to CC-17 and which was multiply resistant to vancomycin,
ampicillin and fluorquinolones.
Acknowledgements
This study was supported by research grant from Instituto de
Salud Carlos III, Fondo de Investigaciones Sanitarias, Ministry
of Health, Spain (Red Espan˜ola de Investigacio´n en Patologı´a
Infecciosa, REIPI; reference RD06/0008/0023), and by the
Direccio´n General de Salud Pu´blica, Ministry of Health, Spain
(reference 1429/05-11).





1. Dahl KH, Simonsen GS, Olsvik et al. Heterogeneity in the vanB
gene cluster of genomically diverse clinical strains of vancomycin-
resistant enterococci. Antimicrob Agents Chemother 1999; 43:
1105–10.
2. Dahl KH, Lundblad EW, Rokenes TP et al. Genetic linkage of the
vanB2 gene cluster to Tn5382 in vancomycin-resistant enterococci and
characterization of two novel insertion sequences. Microbiol 2000; 146:
1469–79.
3. Carias LL, Rudin SD, Donskey CJ et al. Genetic linkage and
cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-
affinity penicillin-binding protein 5 gene in a clinical vancomycin-
resistant Enterococcus faecium isolate. J Bacteriol 1998; 180:
4426–34.
4. Torres C, Escobar S, Portillo A et al. Detection of clonally related
vanB2-containing Enterococus faecium strains in two Spanish hospi-
tals. J Med Microbiol 2006; 55: 1237–43.
5. Lorenzo-Dı´az F, Delgado T, Reyes-Darias JA et al. Characterization
of the first vanB vancomycin-resistant Enterococcus faecium isolated in a
Spanish hospital. Current Microbiol 2004; 48: 199–203.
6. Granlund M, Carlsson C, Edebro H et al. Nosocomial outbreak of
vanB2 vancomycin-resistant Enterococcus faecium in Sweden. J Hosp
Infect 2006; 62: 254–6.
Journal of Antimicrobial Chemotherapy
doi:10.1093/jac/dkm026
Advance Access publication 1 March 2007
Hepatitis B virus resistance to adefovir in a
nucleotide naive patient with chronic hepatitis B
virus infection
B. Ni Laoi1,2, C. Herra3, S. Norris4 and B. Crowley1,5*
1Department of Microbiology, St James’s Hospital, James’s
Street, Dublin 8, Ireland and 2Department of Clinical
Microbiology, University of Dublin, Trinity College, Dublin 2,
Ireland and 3School of Biological Sciences, Dublin Institute
of Technology, Kevin Street, Dublin 8, Ireland and
4Department of Hepatology, St James’s Hospital, James’s
Street, Dublin 8, Ireland; 5National Virus Reference
Laboratory, University College Dublin, Belfield, Dublin 4,
Ireland
Keywords: lamivudine treatment, primary adefovir resistance,
HBV
*Corresponding author. Tel: þ 353-1-4162966; Fax: þ353-1-
4738902; E-mail: bcrowley@stjames.ie
Sir,
Antiviral therapy of chronic hepatitis B (CHB) remains a
major clinical challenge. The new orally active nucleos(t)ide
analogues, such as lamivudine, adefovir and entecavir, have
been shown to be efficacious in controlling viral replication,
decreasing inflammatory activity within the liver and preventing
the progression of CHB infection to liver cirrhosis and hepato-
cellular carcinoma.1 However, due to the spontaneous error rate
of the hepatitis B virus (HBV) polymerase gene and persistence
of HBV in infected individuals, long-term antiviral treatment is
needed in most individuals and therefore increases the risk of
selecting drug-resistant mutants.
Drug resistance is associated with the development of
polymerase gene mutations, followed by a rise in HBV viral
load and a subsequent increase in alanine transaminase levels
with exacerbation of liver disease. Genotypic resistance occurs
in  20% of individuals per year, but at a lower rate in those
treated with adefovir (3% at year 2 and 29% at year 5 of
treatment).2 The major lamivudine resistance mutations in
HBV are located in the highly conserved reverse transcriptase
(rt) domain of the polymerase gene, specifically in the
tyrosine-methionine-aspartate-aspartate (YMDD) motif in the C
domain, at position rtM204I/V. Additional compensatory
mutations are selected downstream in the B domain at positions
rtL180M and rtV173L, which augment drug resistance and
enhance viral replication efficiency in vitro.3 Adefovir resistance
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is associated with mutations located in the B and D domains,
at positions rtA181T/V and rtN236T, respectively.2 Adefovir
is effective in suppressing lamivudine-resistant HBV and,
therefore, is most commonly used in patients with
lamivudine-resistant HBV infection.2 While acquired resistance
to adefovir is important, primary resistance to this nucleotide
analogue was reported recently.4 A variant of HBV was detected
in three non-responders even before they commenced treatment
with adefovir. The associated mutation rtI233V significantly
increased resistance to adefovir in vitro. This variant occurs in
 2% of individuals with CHB.4
In this report, molecular evidence is presented of the emer-
gence of primary adefovir resistance in a patient on prolonged
lamivudine treatment for chronic HBV infection.
A 40-year-old lady presented to St James’s Hospital, Dublin,
with hepatitis Be antigen (HBeAg)-positive chronic HBV infec-
tion in April 1999. A liver biopsy performed in July 1999
showed bridging fibrosis consistent with early cirrhosis. She was
given interferon monotherapy 5 MU daily but this was stopped
after 16 weeks because of severe side effects. She remained
HBeAg-positive at the end of interferon treatment. No HBV
DNA levels were determined before or after interferon treatment.
In July 2000 she was started on lamivudine monotherapy
(100 mg/day). She became HBeAg-negative in April 2003. HBV
DNA was undetectable at this time by hybridization assay
(Digene HCII) (limit of detection 1.4  105 IU/mL). She con-
tinued on lamivudine monotherapy and remained stable until
July 2006 when alanine transaminase levels were noted to be
raised at 46 IU/L (normal range , 35 IU/L). HBV DNA levels
measured by realtime PCR were 5.2Eþ 02 IU/mL (HBV PCR
kit, Artus, Hamburg, Germany) and 3.8Eþ 03 IU/mL (Cobas
Ampliprep/Cobas Taqman HBV test, Roche Diagnostics,
Mannheim, Germany) in July 2004 and June 2006, respectively.
Resistance to lamivudine was suspected. Nucleic acid sequen-
cing of the HBV polymerase gene from sera collected in 2004
and June 2006 was performed as described previously.5
Mutations associated with lamivudine resistance were detected
at positions rtL180M and rtM204V in both samples, with the
rtV173L mutation appearing in serum collected from 2006
(Table 1). The latter mutation did not appear to affect the repli-
cative capacity of HBV since there was no biologically
significant difference in HBV DNA levels in July 2004 and
June 2006. Surprisingly, a mutation associated with adefovir
resistance was identified at position rtA181V in both samples,
although the patient has never been treated with adefovir. She
has now started treatment with tenofovir (300 mg/day).
Genotypic primary resistance to adefovir can occur without
prior adefovir treatment. In this report, the patient received
lamivudine monotherapy for several years and developed the
rtA181V mutation which confers resistance to adefovir.2 This
finding supports a previous report of the emergence of the
rtA181T mutation in 4 of 23 patients on long-term lamivudine
therapy. Similar to the current case, the amino acid substitution at
position 181 appeared concomitantly with the appearance of
YMDD motif mutations.6 The results suggest that amino acid sub-
stitutions at 181 of the HBV polymerase gene may confer resist-
ance to the licensed nucleoside and nucleotide antiviral analogues,
lamivudine and adefovir, respectively. Furthermore, while the
rtI233V mutation has been shown to cause primary adefovir resist-
ance,4 there was no evidence of the mutation in this case. The
emergence of the rtA181V mutation in a patient with no prior
adefovir treatment confirms the need to test for the presence of
adefovir resistance mutations in patients who develop lamivudine
resistance.
This report showed that development of primary adefovir
resistance can be associated with long-term lamivudine mono-
therapy. Furthermore, HBV polymerase gene sequencing should
become part of the treatment monitoring algorithm to improve
treatment efficacy. The amino acid substitution at position 181
may be important in conferring cross-resistance to anti-HBV
drugs and therefore should be investigated further.
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Table 1. Amino acid mutations in the HBV polymerase gene detected by direct nucleic acid sequencing
Associated resistance Muation sites Wild-type
Patient sera
July 2004 June 2006
LAM rt173 V V L
LAM rt180 L M M
ADV rt181 A V V
LAM rt204 M V V
ADV rt233 I I I
ADV rt236 N N N
Note: mutations are shown in bold.
LAM, lamivudine; ADV, adefovir.
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Sir,
Vancomycin-resistant enterococci (VRE) are an infection
control issue in many hospitals, such that rapid, accurate detec-
tion has important clinical consequences. There are five geno-
types responsible for acquired vancomycin resistance (vanA,
vanB, vanD, vanE, vanG), with vanB the most prevalent in
Australia.1,2 Detection of VRE is generally by culture-based
methods, with confirmation of species and van genotype based
on molecular methods.2
The Roche LightCycler VRE Detection Kit (Roche
Diagnostics, Mannheim, Germany) has been developed to
rapidly assess for VRE colonization.3 This kit provides the
primers and the hybridization probes for the amplification and
sequence-specific detection of vanA, vanB1 and vanB2/3, along
with an internal control for detection of sample inhibition. It has
a processing time of approximately 1.5 h. Using this kit with
DNA directly extracted from clinical specimens, detection of
VRE can be reduced to less than 24 h. However, when used in
this manner, it is important to note that the system detects van
genes rather than VRE per se. Thus, the presence of vanB in
non-enterococcal species may influence the sensitivity and
specificity of this approach for detection of VRE.4 – 7
We assessed the usefulness and accuracy of the LightCycler
VRE detection system in the rapid identification of vanB VRE
colonization in 59 faecal samples previously obtained from hos-
pital inpatients (53 haemodialysis, 6 non-haemodialysis patients)
and stored at 280ºC. Twelve of these faecal specimens (from 6
haemodialysis and 6 non-haemodialysis patients) were shown
previously to contain vanB2 Enterococcus faecium, while 42
specimens were repeatedly shown to be culture-negative for
VRE.4 As we have previously reported, four specimens were
shown to be vanB2 anaerobe culture-positive, but were VRE
culture-negative (one specimen contained Clostridium bolteae
and Ruminococcus sp., two specimens contained Clostridium
hathewayi and one specimen contained an un-speciated
Clostridium), while a further specimen contained a vanB2 anae-
robe (C. hathewayi) and vanB2 E. faecium.4 Faecal specimens
were defrosted and DNA was extracted directly from 200–220
mg of faeces using the QIAampw DNA Stool Mini Kit (Qiagen
GmbH, Germany) according to the manufacturer’s recommen-
dations. In addition, 17 h enrichment cultures in antibiotic-free
Enterococcosel broth (BBL, Cockeysville, MD, USA) of these
faecal samples were prepared and DNA extracted as described
previously.4 Control isolates were Enterococcus faecalis ATCC
29212 (van A/B negative), E. faecalis ATCC 51299 (vanB posi-
tive) and a clinical vanA E. faecium isolate obtained from our
institution. All DNA was stored at –20ºC then tested for the pre-
sence of vanA or vanB using the LightCycler VRE Detection
Kit (Roche Diagnostics, Catalogue no. 3 334 996) and the
LightCycler instrument (Roche Diagnostics) with software
version 3.5, according to the manufacturer’s instructions. The
limit of detection was determined by dilution of the plasmid
DNA positive control (1000 copies per 5 mL) provided in the
kit. Dilutions were performed in triplicate with the resulting
standard curve imported into the data analysis mode. The sensi-
tivity and specificity for detection of VRE was calculated.
Statistical differences in the rates of accurate VRE identification
and PCR inhibition were compared using x2/Fisher’s exact test.
All 12 vanB2 E. faecium culture-positive samples were posi-
tive for vanB by LightCycler on both the direct faecal specimen
and the 17 h enrichment culture (100% sensitivity; Table 1).
However, specificity for detecting VRE with LightCycler was
36% and 30% using direct DNA extraction and 17 h enrichment
broth culture, respectively. Of the four specimens known to
contain vanB anaerobes, three of these were positive by
LightCycler by both methods (Table 1). The fourth specimen
was most likely below the limit of detection as this was only
positive following 36 h enrichment broth culture (data not
shown). In addition, the specimen that contained both a vanB2
anaerobe (C. hathewayi) and vanB2 E. faecium was also positive
for vanB by LightCycler. Overall, the LightCycler demonstrated
a lower detection limit of 40 genome equivalents per reaction
(data not shown). The rate of assay inhibition using the
LightCycler procedure was 0% for 17 enrichment broth cultures
and 3% for direct detection, similar to that observed previously
for the Roche LightCycler VRE kit.3
The Roche LightCycler VRE detection assay demonstrates
high sensitivity (100%), but limited specificity (30–36%) for the
detection of vanB VRE in surveillance specimens of faeces. This
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